文献速递白血病

替西罗莫司联合强化再诱导化疗治疗第二次或以上复发急性淋巴细胞白血病的1期试验:儿童肿瘤学组研究(ADVL1114)

A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
PubMed 文献 · Br J Haematol · 2017-03-14

在第二次或以上复发的儿童及青少年急性淋巴细胞白血病中开展1期试验,替西罗莫司联合UKALL R3再诱导化疗。初始剂量为10 mg/m2每周×3次,后续队列为7.5 mg/m2每周×3次或因毒性改为7.5 mg/m2每周×2次。共入组16例,15例可评估毒性;三个剂量水平均出现剂量限制性毒性,联合方案毒性过大不可耐受,但15例中7例获得缓解,3例微小残留病<0.01%。

要点

  • 替西罗莫司联合UKALL R3再诱导化疗在复发ALL儿童中三个剂量水平均出现剂量限制性毒性,毒性过大不可耐受。
  • 15例可评估患者中7例获得缓解,3例微小残留病水平<0.01%。
  • 所有剂量水平均检测到PI3K信号抑制,但早期抑制与再诱导末临床缓解无明显相关性。

核心结论

  • 替西罗莫司加入UKALL R3再诱导治疗导致毒性过大,在复发急性淋巴细胞白血病儿童中不可耐受。
  • 该方案使15例可评估患者中7例获得缓解,3例微小残留病水平<0.01%。
  • 所有替西罗莫司剂量水平均检测到PI3K信号抑制,但早期时间点的抑制与再诱导治疗末的临床缓解无明显相关性。

研究设计与样本

  • 1期试验,对象为第二次或以上复发的儿童及青少年急性淋巴细胞白血病患者,替西罗莫司联合UKALL R3再诱导化疗。
  • 替西罗莫司初始剂量水平(DL1)为10 mg/m2每周×3次;后续队列接受7.5 mg/m2每周×3次(DL0),或因毒性接受7.5 mg/m2每周×2次(DL-1)。
  • 共入组16例患者,其中15例可评估毒性。

主要发现

  • 三个剂量水平均发生剂量限制性毒性,包括高甘油三酯血症、黏膜炎、溃疡、高血压伴可逆性后部白质脑病、γ-谷氨酰转移酶或碱性磷酸酶升高及脓毒症。
  • 15例可评估患者中7例获得缓解,3例微小残留病水平<0.01%。
  • 所有替西罗莫司剂量水平治疗的患者均检测到PI3K信号抑制,但早期时间点的抑制与再诱导治疗末的临床缓解无明显相关性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phosphatidylinositol 3-kinase (PI3K)/mammalian (or mechanistic) target of rapamycin (mTOR) signalling pathway is commonly dysregulated in acute lymphoblastic leukaemia (ALL). A phase 1 trial of the mTOR inhibitor temsirolimus in combination with UKALL R3 re-induction chemotherapy was conducted in children and adolescents with second or greater relapse of ALL. The initial temsirolimus dose level (DL1) was 10 mg/m2 weekly × 3 doses. Subsequent patient cohorts received temsirolimus 7·5 mg/m2 weekly × 3 doses (DL0) or, secondary to toxicity, 7·5 mg/m2 weekly × 2 doses (DL-1). Sixteen patients were enrolled, 15 were evaluable for toxicity. Dose-limiting toxicity (DLT) occurred at all three dose levels and included hypertriglyceridaemia, mucositis, ulceration, hypertension with reversible posterior leucoencephalopathy, elevated gamma-glutamyltransferase or alkaline phosphatase and sepsis. The addition of temsirolimus to UKALL R3 re-induction therapy resulted in excessive toxicity and was not tolerable in children with relapsed ALL. However, this regimen induced remission in seven of fifteen patients. Three patients had minimal residual disease levels <0·01%. Inhibition of PI3K signalling was detected in patients treated at all dose levels of temsirolimus, but inhibition at an early time point did not appear to correlate with clinical responses at the end of re-induction therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rheingold SR, Tasian SK, Whitlock JA, et al. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol. 2017. PMID: 28295182. doi:10.1111/bjh.14569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。